Arnon Karni

Dr. Arnon Karni

Tel Aviv Sourasky Medical Center
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2003 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
AMAlon Monsonego
Alon Monsonego
VZVictor Zota
Victor Zota
Arnon KarniArnon Karni
Arnon Karni
JKJeffery I. Krieger
Jeffery I. Krieger
ABAmit Bar-Or
Amit Bar-Or
HWHoward L. Weiner
Howard L. Weiner
Alzheimer disease (AD) is characterized by the progressive deposition of the 42-residue amyloid β protein (Aβ) in brain regions serving memory and cognition. In animal models of AD, immunization with Aβ results in the clearance of Aβ deposits from the brain. However, a trial of vaccination with synthetic human Aβ1–42 in AD resulted in the development of meningoencephalitis in some patients. We measured cellular immune responses to Aβ in middle-aged and elderly healthy subjects and in patients with AD. A significantly higher proportion of healthy elderly subjects and patients with AD had strong Aβ-reactive T cell responses than occurred in middle-aged adults. The immunodominant Aβ epitopes in humans resided in amino acids 16–33. Epitope mapping enabled the identification of MHC/T cell receptor (TCR) contact residues. The occurrence of intrinsic T cell reactivity to the self-antigen Aβ in humans has implications for the design of Aβ vaccines, may itself be linked to AD susceptibility and course, and appears to be associated with the aging process.

1 October 2005 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
DADavid Azoulay
David Azoulay
VVVeronika Vachapova
Veronika Vachapova
BSBoris Shihman
Boris Shihman
AMAriel Miler
Ariel Miler
Arnon KarniArnon Karni
Arnon Karni

15 September 2006 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
Arnon KarniArnon Karni
Arnon Karni
MAMichal Abraham
Michal Abraham
AMAlon Monsonego
Alon Monsonego
GCGuifang Cai
Guifang Cai
GFGordon J. Freeman
Gordon J. Freeman
HWHoward L. Weiner
Howard L. Weiner
Multiple sclerosis (MS) is postulated to be a T cell-mediated autoimmune disease characterized clinically by a relapsing-remitting (RR) stage followed by a secondary progressive (SP) phase. The progressive phase is felt to be secondary to neuronal degenerative changes triggered by inflammation. The status of the innate immune system and its relationship to the stages of MS is not well understood. Dendritic cells (DCs) are professional APCs that are central cells of the innate immune system and have the unique capacity to induce primary immune responses. We investigated circulating myeloid DCs isolated directly from the blood to determine whether there were abnormalities in myeloid DCs in MS and whether they were related to disease stage. We found that SP-MS subjects had an increased percentage of DCs expressing CD80, a decreased percentage expressing PD-L1, and an increased percentage producing IL-12 and TNF-α compared with RR-MS or controls. A higher percentage of DCs from both RR and SP-MS patients expressed CD40 compared with controls. We then investigated the polarization effect of DCs from MS patients on naive T cells taken from cord blood using a MLR assay. Whereas DCs from RR-MS induced higher levels of Th1 (IFN-γ, TNF-α) and Th2 (IL-4, IL-13) cytokines compared with controls, DCs from SP-MS only induced a polarized Th1 response. These results demonstrate abnormalities of DCs in MS and may explain the immunologic basis for the different stages and clinical patterns of MS.

1 November 1997 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NRNicole Kerlero de Rosbo
Nicole Kerlero de Rosbo
MHMichael Hoffman
Michael Hoffman
IMItzhack Mendel
Itzhack Mendel
IYIsrael Yust
Israel Yust
JKJoel Kaye
Joel Kaye
ABAvraham Ben‐Nun
Avraham Ben‐Nun

1 March 2008 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
DADavid Azoulay
David Azoulay
NUNatali Urshansky
Natali Urshansky
Arnon KarniArnon Karni
Arnon Karni

1 March 1999 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
Arnon KarniArnon Karni
Arnon Karni
RBRonit Bakimer-Kleiner
Ronit Bakimer-Kleiner
OAOded Abramsky
Oded Abramsky
ABAvraham Ben-Nun
Avraham Ben-Nun
MULTIPLE SCLEROSIS (MS) is an acquired and chronic white matter disease of presumed autoimmune pathogenesis. Results of pathologic studies1-4 of the disease and of the animal model—experimental autoimmune encephalomyelitis—emphasize mainly a T-cell basis for an inflammatory reaction of demyelinating plaques. However, beyond the well-known intrathecal overproduction of immunoglobulins in patients with MS,5 there is also clear evidence of humoral immune activity in these plaques.6,7 Results of previous studies8-10 of the frequency of antibodies against myelin oligodendrocyte antigens, such as myelin basic protein (MBP) and galactocerebrosidase in serum and cerebrospinal fluid (CSF), show that elevated titers of these antibodies are not specific for MS. This raises the dilemma of whether these antibodies are deleterious or play a defensive role against further autoimmune attack after myelin breakdown.11